Advertisement
Advertisement

ATNM

ATNM logo

Actinium Pharmaceuticals, Inc

0.80
USD
Sponsored
+0.01
+1.32%
Aug 07, 15:41 UTC -4
Closed
exchange

After-Market

0.81

+0.01
+1.83%

Actinium Pharmaceuticals, Inc Profile

About

Actinium Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company developing ARCs or Antibody Radiation-Conjugates, which combine the targeting ability of antibodies with the cell killing ability of radiation. Actinium's lead application for their ARCs is targeted conditioning, which is intended to selectively deplete a patient's disease or cancer cells and certain immune cells prior to a BMT or Bone Marrow Transplant, Gene Therapy or Adoptive Cell Therapy (ACT) such as CAR-T to enable engraftment of these transplanted cells with minimal toxicities. With their ARC approach, they seek to improve patient outcomes and access to these potentially curative treatments by eliminating or reducing the non-targeted chemotherapy that is used for conditioning in standard practice currently. Their lead product candidate, I-131 apamistamab (Iomab-B) is being studied in the ongoing pivotal Phase 3 Study of Iomab-B in Elderly Relapsed or Refractory Acute Myeloid Leukemia (SIERRA) trial for BMT conditioning. The SI

Info & Links

CEO

Sandesh Seth

Headquarters

100 Park Ave., 23rd Floor
NEW YORK, NY 10017, UNITED STATES

Industry

Medical Drugs

Sector

Medical

Website

www.actiniumpharma.com

Auditor

Marcum LLP

Share holders

100

Employees

25

Actinium Pharmaceuticals, Inc Statistics

Valuation Measures

Market Capitalization2

25.48M

Enterprise Value

-16.65M

Enterprise Value/EBITDA(ttm)

0.67

Price to Earnings Ratio(ttm)

--

Price to Sales(ttm)

--

Price to Book(mrq)

10.72

Price to Cash(ytd)

--

Profitability

Gross Margin(ttm)

25.00%

Operating Margin(ttm)

--

Profit Margin(ttm)

-1425.28%

Return on Equity(ttm)

-218.66%

Return on Invested Capital(ttm)

-388.88%

Return on Assets(ttm)

-43.39%

Income Statement

Revenue(ttm)

90.00K

Revenue Per Share(ttm)

0.00

Gross Profit(ttm)

90.00K

EBITDA(ttm)3

-24.68M

Net Income Available to Common(ttm)

-23.47M

Diluted EPS(ttm)

-0.75

Share Statistics

Beta (5Y Monthly)

0.01

52-Week Change

-48.88%

S&P 500 52-Week Change

21.72%

S&P 500 Member

No

Stock Optionable

Yes

Total Shares Outstanding1

31.37M

Dividend Yield

0.00%

Float4

31.19M

% Held by Insiders

0.60%

% Held by Institutions

27.50%

Balance Sheet

Total Cash(mrq)

42.13M

Total Cash Per Share(mrq)

1.34

Total Debt(mrq)

8.00K

Total Debt/Equity(mrq)

0.35%

Current Ratio(mrq)

5.89%

Quick Ratio(mrq)

5.89%

Book Value Per Share(mrq)

0.07

Cash Flow

Operating Cash Flow Per Share(ytd)

-0.19

Free Cash Flow(ytd)

-5.87M

Table Key

mrq = Most Recent Quarter

ttm = Trailing Twelve Months

ytd = Year To Date

Footnotes

Data provided by Zacks Investment Research or calculated by FXEmpire. All numbers are rounded to the closest decimal.

  • 1 Total Shares outstanding is taken from the most recently filed quarterly or annual report.
  • 2 Market Cap is calculated using total shares outstanding and the most recent share price.
  • 3 EBITDA is calculated using methodology that may differ from that used by a company in its reporting.
  • 4 The float is a measure of the number of shares available for trading by the public. It's calculated by taking the number of issued and outstanding shares minus any restricted stock, which might not be publicly traded.
Advertisement